Screening of deceased organ donors: No easy answers

Transplantation

Volumn 91, Issue 2, 2011, Pages 146-149

  Huang, Robert C ^a   Fishman, Jay A ^b  

^a UCSD MEDICAL CENTER   (United States)

^b MASSACHUSETTS GENERAL HOSPITAL   (United States)

Author keywords

Donor derived infection; Human T cell lymphotropic virus; Infection; Microbiologic screening; Organ donation

Indexed keywords

ARTICLE; CADAVER DONOR; DIAGNOSTIC ACCURACY; DIAGNOSTIC TEST; DISEASE TRANSMISSION; HUMAN; HUMAN T CELL LEUKEMIA VIRUS 1; HUMAN T CELL LEUKEMIA VIRUS 2; INFECTION; INFECTION RISK; MICROBIOLOGICAL EXAMINATION; NONHUMAN; ORGAN TRANSPLANTATION; PREVALENCE; PRIORITY JOURNAL; SCREENING; SENSITIVITY AND SPECIFICITY; VIRUS DIAGNOSIS;

COMMUNICABLE DISEASES; DISEASE TRANSMISSION, INFECTIOUS; HUMAN T-LYMPHOTROPIC VIRUS 1; HUMAN T-LYMPHOTROPIC VIRUS 2; HUMANS; MASS SCREENING; MICROBIOLOGICAL TECHNIQUES; TISSUE AND ORGAN PROCUREMENT; TISSUE DONORS; UNITED STATES;

EID: 78751641265     PISSN: 00411337     EISSN: None     Source Type: Journal    
DOI: 10.1097/TP.0b013e3181ffb9bb     Document Type: Article

References (28)

1. Siegel RS, Gartenhaus RB, Kuzel TM. Human T-cell lymphotropic-I- associated leukemia/lymphoma.Curr Treat Options Oncol 2001; 2:291.
2. Uchiyama T, Yodoi J, Sagawa K, et al. Adult T-cell leukemia: Clinical and hematologic features of 16 cases. Blood 1977; 50: 481.
3. Osame M, Usuku K, Izumo S, et al. HTLV-I associated myelopathy, a new clinical entity. Lancet 1986; 1: 1031.
4. Yamaguchi K. Human T-lymphotropic virus type I in Japan. Lancet 1994; 343: 213.
5. Poiesz BJ, Papsidero LD, Ehrlich G, et al. Prevalence of HTLV-I-associated T-cell lymphoma. Am J Hematol 2001; 66: 32.
6. Kamihira S, Nakasima S, Oyakawa Y, et al. Transmission of human T cell lymphotropic virus type I by blood transfusion before and after mass screening of sera from seropositive donors.Vox Sang 1987; 52: 43.
7. Kaul DR, Taranto S, Alexander C, et al. Donor screening for human T-cell lymphotrophic virus 1/2: Changing paradigms for changing testing capacity. Am J Transplant 2010; 10: 207.
8. Kauffman HM, Taranto SE. Human T-cell lymphotrophic virus type-1 and organ donors. Transplantation 2003; 76: 745.
9. Ison MG, Hager J, Blumberg E, et al. Donor-derived disease transmission events in the united states: Data reviewed by the OPTN/UNOS disease transmission advisory committee. Am J Transplant 2009; 9: 1929.
10. Marvin MR, Brock GN, Kwarteng K, et al. Increasing utilization of human T-cell lymphotropic virus ( + ) donors in liver transplantation: Is it safe? Transplantation 2009; 87: 1180.
11. Nakatsuji Y, Sugai F, Watanabe S, et al. HTLV-I-associated myelopathy manifested after renal transplantation. J Neurol Sci 2000; 177: 154.
12. Ozden S, Seilhean D, Gessain A, et al. Severe demyelinating myelopathy with low human T cell lymphotropic virus type 1 expression after transfusion in an immunosuppressed patient. Clin Infect Dis 2002; 34: 855.
13. Remesar MC, Del Pozo AE, Pittis MG, et al. Transmission of HTLV-I by kidney transplant. Transfusion 2000; 40: 1421.
14. Toro C, Rodes B, Poveda E, et al. Rapid development of subacute myelopathy in three organ transplant recipients after transmission of human T-cell lymphotropic virus type I from a single donor. Transplantation 2003; 75: 102.
15. Jenks PJ, Barrett WY, Raftery MJ, et al. Development of human T-cell lymphotropic virus type I-associated adult T-cell leukemia/lymphoma during immunosuppressive treatment following renal transplantation. Clin Infect Dis 1995; 21: 992.
16. Tanabe K, Kitani R, Takahashi K, et al. Long-term results in human T-cell leukemia virus type 1-positive renal transplant recipients. Transplant Proc 1998; 30: 3168.
17. Freeman RB, Cohen JT. Transplantation risks and the real world: What does 'high risk' really mean? Am J Transplant 2009; 9: 23.
18. Nowicki MJ, Matsuoka L, Brucal D, et al. High seroprevalence of anti-HTLV-I/II antibodies among solid organ donors necessitates confirmatory testing. Transplantation 2006; 82: 1210.
19. Abbott. PRISM HTLV-I/HTLV-II, List No. 6E50, 34-4547/R2, U.S. License No. 43. 2009.
20. Ahn J, Cohen SM. Transmission of human immunodeficiency virus and hepatitis C virus through liver transplantation. Liver Transpl 2008; 14: 1603.
21. Kucirka LM, Namuyinga R, Hanrahan C, et al. Provider utilization of high-risk donor organs and nucleic acid testing: Resultsof two national surveys. Am J Transplant 2009; 9: 1197.
22. Humar A, Morris M, Blumberg E, et al. Nucleic acid testing (NAT) of organ donors: Is the 'best' test the right test? A consensus conference report. Am J Transplant 2010; 10: 889.
23. Palacios G, Druce J, Du L, et al. A new arenavirus in a cluster of fatal transplant-associated diseases. N Engl J Med 2008; 358: 991.
24. Peleg AY, Husain S, Kwak EJ, et al. Opportunistic infections in 547 organ transplant recipients receiving alemtuzumab, a humanized monoclonal CD-52 antibody. Clin Infect Dis 2007; 44: 204.
25. Iwamoto M, Jernigan DB, Guasch A, et al. Transmission of West Nile virus from an organ donor to four transplant recipients. N Engl J Med 2003; 348: 2196.
26. Kun H, Moore A, Mascola L, et al. Transmission of Trypanosoma cruzi by heart transplantation. Clin Infect Dis 2009; 48: 1534.
27. Sosa-Estani S, Viotti R, Segura EL. Therapy, diagnosis and prognosis of chronic Chagas disease: Insight gained inArgentina.Mem Inst Oswaldo Cruz 2009; 104(suppl 1): 167.
28. Toro C, Benito R, Aguilera A, et al. Infection with human T lympho-tropic virus type I in organ transplant donors and recipients in Spain. J Med Virol 2005; 76: 268.